Results 31 to 40 of about 463,157 (302)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

open access: yesBMC Cancer, 2022
Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli   +3 more
doaj   +1 more source

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

open access: yesMolecules, 2022
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex.
Shabnam Shaabani   +12 more
doaj   +1 more source

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events

open access: yesChinese Journal of Lung Cancer, 2020
As a new method, immunotherapy which is targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) plays a more and more important role in the treatment of malignant tumors.
Tongji XIE, Shouzheng WANG, Puyuan XING
doaj   +1 more source

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials

open access: yesFrontiers in Oncology, 2021
BackgroundProgrammed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor activity in patients with platinum-resistant urothelial cancer (UC).
Zaishang Li   +20 more
doaj   +1 more source

Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]

open access: yes, 2012
A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin   +5 more
core   +1 more source

Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence

open access: yesBrain Sciences, 2022
Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods: From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were ...
Wei Yu   +5 more
doaj   +1 more source

Diversification of a protein kinase cascade: IME-2 is involved in nonself recognition and programmed cell death in Neurospora crassa. [PDF]

open access: yes, 2012
Kinase cascades and the modification of proteins by phosphorylation are major mechanisms for cell signaling and communication, and evolution of these signaling pathways can contribute to new developmental or environmental response pathways.
Bueche, Joanna A   +2 more
core   +2 more sources

Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors 
of Small Cell Lung Cancer

open access: yesChinese Journal of Lung Cancer, 2020
Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer.
Yaning YANG, Yan WANG
doaj   +1 more source

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study

open access: yesFrontiers in Immunology, 2023
BackgroundMultiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unclear.
Yu-Feng Huang   +9 more
doaj   +1 more source

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis [PDF]

open access: yes, 2014
INTRODUCTION: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to eradicate invading pathogens and increased susceptibility to secondary infections.
Andriani C Patera   +13 more
core   +2 more sources

Home - About - Disclaimer - Privacy